Skip to content

S. 4472 · 119th Congress (2025–2027)

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.

The bill reauthorizes

  • grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,
  • grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and
  • a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.

Also, the bill revises the NIH grants to require (1) the NIH, in considering grant renewal, to assess available information on the safety and efficacy of the investigational drugs; (2) grantees to promptly report available safety data from ongoing clinical trials; and (3) the NIH to determine the timeframe for enrollment in clinical trials for the investigational drugs.

Additionally, every five years, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, for ALS and other rare neurodegenerative diseases. Each plan must include the FDA's previous actions and recommendations for improvements.

Finally, the Government Accountability Office and the Department of Health and Human Services must report on the impacts of these grants.

Show official title

A bill to amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.

Passed Senate

This bill’s path

96 days after it was introduced

This is S. 4472’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced3 months

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

Sponsor
Sen. Lisa Murkowski (R-AK)
Cosponsors
15 cosponsors

1 original · 14 later

7 R · 8 D

  1. Sen. Christopher A. Coons (D-DE)· Original · Apr 30, 2026
  2. Sen. Susan M. Collins (R-ME)· Later · Jun 15, 2026
  3. Sen. Shelley Moore Capito (R-WV)· Later · Jun 15, 2026
  4. Sen. Amy Klobuchar (D-MN)· Later · Jun 15, 2026
  5. Sen. Alex Padilla (D-CA)· Later · Jun 15, 2026
  6. Sen. Jim Banks (R-IN)· Later · Jun 16, 2026
  7. Sen. John R. Curtis (R-UT)· Later · Jun 16, 2026
  8. Sen. Kirsten E. Gillibrand (D-NY)· Later · Jun 16, 2026
  9. Sen. Margaret Wood Hassan (D-NH)· Later · Jun 16, 2026
  10. Sen. Steve Daines (R-MT)· Later · Jun 24, 2026
  11. Sen. Edward J. Markey (D-MA)· Later · Jun 24, 2026
  12. Sen. Jeff Merkley (D-OR)· Later · Jul 21, 2026
  13. Sen. David McCormick (R-PA)· Later · Jul 21, 2026
  14. Sen. John Barrasso (R-WY)· Later · Jul 23, 2026
  15. Sen. Sheldon Whitehouse (D-RI)· Later · Jul 23, 2026
Policy area
Health
Subjects
  • Department of Health and Human Services
  • Drug therapy
  • Food and Drug Administration (FDA)
  • Government information and archives
  • Health programs administration and funding
  • Internet, web applications, social media
  • Medical research
  • National Institutes of Health (NIH)
  • 3 more
    • Neurological disorders
    • Public-private cooperation
    • Research administration and funding

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. ▸ 3 committee actions · Apr 30, 2026 – Jul 16, 2026
    1. Referred to committee

      Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

      Sources
    2. Ordered reported

      Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.

      Sources
    3. Reported by committee

      Committee on Health, Education, Labor, and Pensions. Reported by Senator Cassidy with an amendment in the nature of a substitute. Without written report.

      Sources
  3. Latest

    Passed Senate

    Congressional Record S4425-4426; text: CR S4425-4426

    Passed Senate with an amendment by Voice Vote.

    The Senate passed the amended bill.

    Document: Engrossed in Senate

    Sources

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Apr 30, 2026 · Markup Jun 17, 2026 · Reported Jul 16, 2026
    1. Jun 17, 2026 · Open business meeting

Floor record

i

Explicit consideration evidence: the measure’s bill-status citation matched a GovInfo title, headline, or first paragraph. Incidental mentions are not listed.

  1. Aug 4, 2026 · Senate · Passed Senate with an amendment by Voice VoteCongressional Record S4425–S4426

    Accelerating Access to Critical Therapies for Als Reauthorization Act of 2026

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Reported to Senate
Engrossed in Senate
Titles (2)
  1. Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

    Display title, Short title · Engrossed in Senate, Reported to Senate, Introduced in Senate

  2. A bill to amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.

    Official title · Introduced in Senate